Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence
- PMID: 19248218
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence
Comment on
-
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38. Neurology. 2008. PMID: 18316689
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical